ADC binds TROP2 on tumor cells, is internalized, and releases an exatecan-derived topoisomerase I inhibitor (SHR9265) after linker cleavage, causing DNA damage/replication inhibition leading to cell-cycle arrest and apoptosis (with possible bystander effect).